Cover Image
市場調查報告書

B型流行性感冒嗜血桿菌感染疾病:開發中產品分析

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 255972
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
B型流行性感冒嗜血桿菌感染疾病:開發中產品分析 Haemophilus influenzae Type B Infections - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 59 Pages
簡介

B型流感嗜血桿菌(Hib)是一種容易導致嚴重疾病並危及生命的感染細菌,尤其在兒童身上。症狀包括嚴重的頭痛,頸部僵硬,抽搐或癲癇發作,嚴重嗜睡,難以清醒,意識喪失或呼吸困難。誘發因素包括年齡和免疫系統衰弱。治療包括抗生素。

本報告提供全球B型流行性感冒嗜血桿菌感染疾病治療藥之開發趨勢調查,提供開發中產品的各開發階段比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估等資訊。

簡介

  • 調查範圍

B型流行性感冒嗜血桿菌感染疾病概要

治療藥的開發

  • 開發中產品的概要
  • 各企業治療藥
  • 各大學/機關治療藥
  • 企業開發中的產品
  • 大學/機關研究中的產品

治療藥的評估

  • 標的別
  • 各給藥途徑
  • 各分子類型

B型流行性感冒嗜血桿菌感染疾病的開發治療藥的企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Biological E. Limited
  • 第一三共
  • GlaxoSmithKline Plc
  • Indian Immunologicals Limited
  • 化血研
  • LG Life Science LTD.
  • Panacea Biotec Limited
  • Sanofi
  • Sanofi Pasteur SA
  • Shantha Biotechnics Ltd
  • Zydus Cadila Healthcare Ltd

藥物簡介

暫停中的計劃

成為了中止的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9806IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H2 2017, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape.

Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious illness, especially in children. Symptoms include severe headache, stiff neck, convulsions or seizures, severe drowsiness, difficulty waking up, loss of consciousness or difficulty with breathing. Predisposing factors include age and weakened immune system. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 6, 2, 3, 2 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Haemophilus influenzae Type B Infections - Overview
    • Haemophilus influenzae Type B Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Haemophilus influenzae Type B Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Biological E Ltd
    • Cadila Healthcare Ltd
    • Chongqing Zhifei Biological Products Co Ltd
    • Daiichi Sankyo Co Ltd
    • GlaxoSmithKline Plc
    • Indian Immunologicals Ltd
    • Kaketsuken
    • LG Chem Ltd
    • Sanofi
    • Sanofi Pasteur SA
    • Serum Institute of India Ltd
    • Shantha Biotechnics Pvt Ltd
  • Haemophilus influenzae Type B Infections - Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Haemophilus influenzae [serotype B] + meningococcal) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BK-1310 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DTaP-IPV-HB-PRPT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Haemophilus influenzae B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Haemophilus influenzae B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hemophilus influenza [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-Hib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Haemophilus influenzae Type B Infections - Dormant Projects
  • Haemophilus influenzae Type B Infections - Discontinued Products
  • Haemophilus influenzae Type B Infections - Product Development Milestones
    • Featured News & Press Releases
      • Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5
      • Nov 10, 2014: Shantha's Pentavalent Pediatric Vaccine launched in India
      • May 05, 2014: Shantha's Pentavalent Pediatric Vaccine prequalified by World Health Organization
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Haemophilus influenzae Type B Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by Biological E Ltd, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by Cadila Healthcare Ltd, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by Indian Immunologicals Ltd, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by Kaketsuken, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by LG Chem Ltd, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by Sanofi, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by Sanofi Pasteur SA, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by Serum Institute of India Ltd, H2 2017
  • Haemophilus influenzae Type B Infections - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017
  • Haemophilus influenzae Type B Infections - Dormant Projects, H2 2017
  • Haemophilus influenzae Type B Infections - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Haemophilus influenzae Type B Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top